Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 01:23:32 2024-04-26 pm EDT			5-day change	1st Jan Change
0.03 ^CAD	+20.00%		0.00%	0.00%

Apr. 23	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
Apr. 23	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023

November 28, 2023

Revive Therapeutics Ltd. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was CAD 0.390623 million compared to CAD 1.66 million a year ago.

Latest news about Revive Therapeutics Ltd.

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	Apr. 23	MT
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	Apr. 23	MT
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	Apr. 18	MT
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	Apr. 18	MT
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	Apr. 18	CI
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	Apr. 02	MT
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	Apr. 02	CI
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	Mar. 27	MT
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	Mar. 27	CI
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	Mar. 19	MT
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	Mar. 19	CI
Revive Therapeutics Provides Corporate Update	Mar. 12	MT
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 28	CI
Revive Therapeutics Ltd. announced that it has received CAD 2.10061 million in funding	Feb. 25	CI
Revive Therapeutics Exploring Use of Bucillamine for Long COVID	Feb. 01	MT
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	Feb. 01	CI
Revive Therapeutics Announces Offering of Up to $3 Million	Jan. 25	MT
Revive Therapeutics Ltd. announced that it expects to receive CAD 3 million in funding	Jan. 23	CI
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	Jan. 16	CI
Revive Therapeutics Says Completed Development of a Novel Lyophilized Formulation of Bucillamine	Jan. 10	MT
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	Jan. 10	CI
Revive Therapeutics Re-Appoints CEO, CFO	Dec. 20	MT
Revive Therapeutics Collaborates with Attwill Medical Solutions to Develop Novel Lyophilized Formulation of Bucillamine	Dec. 18	MT
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of A Novel Lyophilized Formulation of Bucillamine	Dec. 18	CI
Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 28	CI

Chart Revive Therapeutics Ltd.

Duration

Period

More charts

Company Profile

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Companyâs cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REVIVE THERAPEUTICS LTD.	0.00%	9.17M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs